• ADBiotech revised terms for its KRW 2 billion convertible bond issuance in an Oct. 29, 2026, correction.
• The coupon rises to 3.5% from 0%; the maturity yield increases to 5% from 3%.
• Maturity moves to Nov. 6, 2029, from Oct. 29, 2031; payment shifts to Nov. 6, 2026, from Oct. 29, 2026.
• The conversion price falls to KRW 1,999 from KRW 2,021, increasing potential new shares to 1,000,500 from 989,609.
• JK New Technology Investment Partnership No. 18 replaces K Polaris Investment Partnership as the bond subscriber.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADBiotech Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261029000672), on October 30, 2026, and is solely responsible for the information contained therein.